Back to All Articles
You must be logged in to create a new articleBrowse articles with tag: Drugs
All Articles
Intra-Cellular Therapies Surges 15% Following Settlement of Caplyta ANDA Litigation with Sandoz
Shares of Intra-Cellular Therapies (NASDAQ: ITCI) increased by nearly 15% last week after the company reached a significant settlement with... Read More
Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation
Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma... Read More
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Corcept Therapeutics Faces Share Price Plunge After Losing Teva Patent Battle
Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in... Read More
Pharmaceutical Patents Set to Expire in 2024: Implications and Opportunities
Source: https://www.greyb.com/blog/drug-patents-expiring-2024/ The pharmaceutical industry is undergoing a important phase as numerous patents for key drugs are slated to expire... Read More
The U.S. Supreme Court is About to Ultimately Decide Amgen vs Sanofi Antibody Patent Case
Most of the community involved in life science litigation and pharmaceutical companies, thought they saw the end of the long-fought... Read More